"Obesity wonder drugs Wegovy and Zepbound are already showing that they can reduce the risk of cardiovascular and chronic kidney disease in addition to helping people lose weight. Now, a US-wide trial will test whether tirzepatide, the active ingredient in Zepbound, may be an effective treatment for people with long Covid. Part of a class of drugs known as GLP-1s, tirzepatide acts on receptors in the gut and the brain to regulate appetite."
"As many as 20 million people in the US have experienced long Covid, a chronic condition that lasts for at least three months after an initial infection. While more than 200 symptoms of long Covid have been documented, some of the most common include coughing, shortness of breath, brain fog, fatigue, mood changes, trouble sleeping, and body aches. Scientists still don't fully understand how and why long Covid occurs, but they've found persistent inflammation in many patients."
Wegovy and Zepbound have shown reductions in cardiovascular and chronic kidney disease risks in addition to weight loss. Tirzepatide, the active ingredient in Zepbound and a member of the GLP-1 class, acts on gut and brain receptors to suppress appetite and reduce food intake. Observed cardiovascular and renal benefits exceed explanations based on weight loss alone, with mounting evidence pointing to a broad body-wide anti-inflammatory effect. Long Covid affects up to 20 million people in the US, marked by persistent symptoms and chronic inflammation that may stem from lingering virus or autoantibodies. Researchers aim to evaluate tirzepatide's ability to reduce inflammation and improve long Covid symptoms.
Read at WIRED
Unable to calculate read time
Collection
[
|
...
]